"Until there's an
equivalent or better option at a lower price, I believe payers will cover
Trikafta when prescribed for the indicated population. I don’t see a much
cheaper or better option coming to market anytime soon."
— Yusuf Rashid, R.Ph., vice president of pharmacy and vendor
relationship management at Community Health Plan of Washington, spoke with
AIS's Health Plan Weekly
about how payers plan to cover Trikafta, a new cystic fibrosis therapy from
Vertex Pharmaceuticals that some in the industry are already calling a
game-changer.
No comments:
Post a Comment